Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients' lives. The company is a leader in targeted protein degradation (TPD), a next-generation small molecule therapeutic modality that engages the body's natural cellular recycling system to selectively eliminate disease-causing proteins. The current discovery and development efforts are primarily directed at high-value targets in immunology. The company believes there are more than 160 million patients in the United States, Europe and Japan that are diagnosed with some of the most prevalent immune-inflammatory diseases that its programs have the potential to address, nearly half of whom remain untreated. Of those treated, most patients are treated with therapies that do not treat the underlying diseases but mostly their symptoms. As a result, only a small percentage of patients, which the company believes to be approximately 3% ¹ of the diagnosed population with moderate to severe inflammatory diseases, are currently treated with systemic advanced therapies, mostly injectable biologics.

The biotechnology industry is extremely competitive in the race to develop new products. Companies developing small molecule protein degraders therapies for patients include, but are not limited to, Arvinas, Inc., C4 Therapeutics, Inc., Nurix Therapeutics, Inc., and Foghorn Therapeutics, Inc. Further, several pharmaceutical companies have disclosed preclinical investments in this field. In particular, several pharmaceutical companies have announced partnerships around programs targeting STAT6, including Gilead Sciences, Inc, Johnson & Johnson, Pfizer and Sanofi. Many of the indications targeted by the company's programs have approved standards of care which may include more traditional therapeutic modalities. The company believes it has significant competitive advantages with its years of expertise in targeted protein degradation, clinical development expertise, and intellectual property position.

The company generates revenue through research collaboration arrangements with Vertex Pharmaceuticals Incorporated, Sanofi S.A., and Gilead Sciences, Inc. To date, the company has not generated any revenue from product sales and does not expect to generate any revenue from the sale of products in the foreseeable future. The company's only revenues have been derived from these collaboration arrangements. The company intends to leverage its drug development expertise to become a fully integrated biopharmaceutical company with an industry-leading pipeline of novel medicines.

The company's publicly disclosed immunology programs target STAT6, IRF5 and IRAK4. The company is developing KT-621 as part of its STAT6 program, and recently initiated the BROADEN2 Phase 2b clinical trial in adult and adolescent patients with moderate to severe Atopic Dermatitis (AD) and the BREADTH Phase 2b clinical trial in adult patients with moderate to severe asthma. The company is also developing KT-579 as part of its oral IRF5 degrader program, and recently initiated a Phase 1 clinical trial in healthy volunteers. The company is collaborating with Sanofi on the development of its IRAK4 degrader, KT-485/SAR447971, which Sanofi plans to advance into clinical testing in 2026. In June 2025, the company announced a strategic collaboration with Gilead to develop novel oral molecular glue degraders for CDK2. The company's additional early undisclosed pipeline programs focus on addressing high impact targets that have been elusive to conventional modalities.

In 2025, the company completed a first-in-human Phase 1 trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of KT-621 compared to placebo in a total of 118 ² healthy volunteers. The company also conducted a Phase 1b study evaluating KT-621 in patients with moderate to severe AD. The KT-621 BroADen Phase 1b clinical trial was an open-label, single-arm study that enrolled 22 ³ patients with moderate to severe AD across two dose levels, 100 mg and 200 mg of KT-621 once daily for 28 days. In June 2025, the company entered into an exclusive option and license agreement with Gilead Sciences to accelerate the development and commercialization of a novel molecular glue degrader program targeting cyclin-dependent kinase 2 (CDK2). Under the Gilead Agreement, the company received a non-refundable upfront payment of $40.0 million ⁴. In June 2025, under the terms of the Sanofi Agreement, Sanofi decided to exercise its participation election right for the IRAK4 degraders, including KT-485/SAR447971. In the first quarter of 2025, the company achieved a development milestone related to certain preclinical activities associated with the IRAK4 program, in connection with which the company unconstrained $20.0 million ⁵ of consideration. In December 2025, the company received Fast Track Designation for KT-621 for atopic dermatitis.

The company has incurred significant operating losses since inception. For the years ended December 31, 2025, 2024 and 2023, the company reported net losses of $311.4 million ⁶, $223.9 million ⁷ and $147.0 million ⁸, respectively. As of December 31, 2025, the company had an accumulated deficit of $1,066.0 million ⁹. As of December 31, 2025, the company's cash and cash equivalents and marketable securities were $1,619.4 million ¹⁰. Collaboration revenues were $39.2 million ¹¹ for the year ended December 31, 2025, compared to $47.1 million ¹² for the year ended December 31, 2024. Research and development expenses were $316.6 million ¹³ for the year ended December 31, 2025, compared to $240.2 million ¹⁴ for the year ended December 31, 2024.

The company expects to advance at least one new molecular entity into clinical testing annually. The company expects its expenses to significantly increase in connection with its ongoing activities, as it initiates and completes preclinical studies and clinical trials for current or future product candidates, prepares and submits INDs with the FDA for future product candidates, develops and scales up capabilities, advances research and development related activities to expand its product pipeline, seeks regulatory approval for product candidates that successfully complete clinical development, contracts to manufacture product candidates, maintains, expands and protects its intellectual property portfolio, hires additional staff, and incurs additional costs associated with continuing to operate as a public company. The company believes the existing cash, cash equivalents and marketable securities of $1,619.4 million ¹⁵ as of December 31, 2025, will be sufficient to fund its operations into 2029 ¹⁶.

The company is developing KT-621 as part of its STAT6 program, and recently initiated the BROADEN2 Phase 2b clinical trial in adult and adolescent patients with moderate to severe Atopic Dermatitis (AD) and the BREADTH Phase 2b clinical trial in adult patients with moderate to severe asthma. Two parallel Phase 2b trials to evaluate KT-621 in patients with moderate to severe AD and asthma are ongoing with data expected by mid-2027 ¹⁷ and late-2027 ¹⁸, respectively. The company is also developing KT-579 as part of its oral IRF5 degrader program, and recently initiated a Phase 1 clinical trial in healthy volunteers. The company is collaborating with Sanofi on the development of its IRAK4 degrader, KT-485/SAR447971, which Sanofi plans to advance into clinical testing in 2026 ¹⁹. In June 2025, the company announced a strategic collaboration with Gilead to develop novel oral molecular glue degraders for CDK2. Under the Gilead Agreement, if Gilead exercises the option, the company is entitled to receive an option exercise payment of $45.0 million ²⁰ and will be eligible to receive up to $665.0 million ²¹ upon the achievement of certain development, regulatory and commercial milestones.

The company expects its expenses to significantly increase in connection with its ongoing activities. The company expects to continue to incur significant expenses and increasing operating losses over the next several years and for the foreseeable future. The company expects its expenses to increase substantially in connection with its ongoing activities, particularly as it advances the later-stage clinical development of its product candidates. In addition, the company expects to incur additional costs associated with operating as a public company.

As of December 31, 2025, the company had 238 ²² full-time employees. Within its workforce, 189 ²³ employees are engaged in research and development and 49 ²⁴ are engaged in business development, finance, legal, and general management and administration. The company expects to increase its number of employees and the scope of its operations. The company's corporate headquarters are located in Watertown, Massachusetts, where it leases and occupies approximately 100,624 ²⁵ square feet of office and laboratory space. Additionally, the company leases 34,522 ²⁶ square feet of office and laboratory space in Watertown that it is not currently occupying. The company intends to sublease and is actively marketing the additional space to third parties.

The company expects to continue to incur significant expenses and increasing operating losses over the next several years and for the foreseeable future. The company expects its expenses to significantly increase in connection with its ongoing activities, as it initiates and completes preclinical studies and clinical trials for current or future product candidates, prepares and submits INDs with the FDA for future product candidates, develops and scales up capabilities, advances research and development related activities to expand its product pipeline, seeks regulatory approval for product candidates that successfully complete clinical development, contracts to manufacture product candidates, maintains, expands and protects its intellectual property portfolio, hires additional staff, and incurs additional costs associated with continuing to operate as a public company. The company believes the existing cash, cash equivalents and marketable securities of $1,619.4 million ²⁷ as of December 31, 2025, will be sufficient to fund its operations into 2029 ²⁸.

The company will need to raise substantial additional funding. If the company is unable to raise capital when needed or on attractive terms, it would be forced to delay, scale back or discontinue some of its product candidate development programs or future commercialization efforts. The company's future capital requirements will depend on, and could increase significantly as a result of, many factors, including the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for its current or future product candidates, the scope, prioritization and number of its research and development programs, the costs, timing and outcome of regulatory review of its current or future product candidates, its ability to establish and maintain additional collaborations on favorable terms, the achievement of milestones or occurrence of other developments that trigger payments under any existing or additional collaboration agreements, the extent to which it is obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing its intellectual property rights and defending intellectual property-related claims, the extent to which it acquires or in-licenses other current or future product candidates and technologies, the costs of securing manufacturing arrangements for commercial production, and the costs of establishing or contracting for sales and marketing capabilities if it obtains regulatory clearances to market its current or future product candidates.

The company's approach to the discovery and development of product candidates is novel and unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products. The company utilizes a method known as targeted protein degradation (TPD) to discover and develop product candidates. No product candidate using a heterobifunctional degrader has been approved in the United States or Europe, and the data underlying the feasibility of developing such therapeutic products is both preliminary and limited. The company is very early in its development efforts and its STAT6 and IRF5 programs are in early clinical development with additional programs in preclinical development. If the company is unable to advance its programs into and through the clinic for safety or efficacy reasons or commercialize its product candidates or experience significant delays in doing so, its business will be materially harmed.

Unstable global economic and geopolitical conditions may have serious adverse consequences on the company's business, financial condition, stock price and results of operations. The company is subject to risks related to changes in U.S. federal policy that affect the geopolitical landscape, including tariffs. On September 25, 2025, the current U.S. administration announced a 100% ²⁹ tariff on brand-name or patented drugs unless pharmaceutical companies expand their manufacturing operations in the U.S. The current U.S. administration has expressed an intent to impose tariffs on pharmaceutical imports. The U.S. government has imposed substantial tariffs on most countries throughout the world and has further threatened to continue to broadly impose tariffs, which could lead to corresponding punitive actions by the countries with which the U.S. trades.

Management's message emphasizes the company's commitment to advancing novel technologies to address targets that have known disease-causing biology but which have not been drugged, or have been inadequately drugged. The company intends to leverage its drug development expertise to become a fully integrated biopharmaceutical company with an industry-leading pipeline of novel medicines. Key strategic priorities include advancing existing clinical and preclinical programs through critical inflection points that are believed will de-risk the molecules and approach, expanding the therapeutic pipeline by continuing to identify high-value targets that have disruptive therapeutic potential and that are well-suited for the company's approaches, continuing to invest in capabilities to identify novel molecules that address elusive targets and optimize them to highly specific drug candidates, developing a broad patent estate and expecting to expand and protect proprietary know-how and intellectual property, building organizational capabilities to advance the goal of becoming a fully integrated biopharmaceutical company, and continuing to consider synergistic collaboration opportunities. The company believes the existing cash, cash equivalents and marketable securities of $1,619.4 million ³⁶ as of December 31, 2025, will be sufficient to fund its operations into 2029 ³⁷.

For the year ended December 31, 2025, total collaboration revenue was $39.2 million ³⁸, compared to $47.1 million ³⁹ for the year ended December 31, 2024. Net loss was $311.4 million ⁴⁰ for 2025, compared to $223.9 million ⁴¹ for 2024. Net loss per share attributable to common stockholders, basic and diluted, was $3.69 ⁴² for 2025, compared to $2.98 ⁴³ for 2024. Research and development expenses were $316.6 million ⁴⁴ for 2025, compared to $240.2 million ⁴⁵ for 2024. General and administrative expenses were $68.2 million ⁴⁶ for 2025, compared to $63.5 million ⁴⁷ for 2024. Impairment of long-lived assets was $3.9 million ⁴⁸ for 2025, compared to $4.9 million ⁴⁹ for 2024. Other income, net was $38.0 million ⁵⁰ for 2025, compared to $37.8 million ⁵¹ for 2024. As of December 31, 2025, the company had cash and cash equivalents and marketable securities of $1,619.4 million ⁵² and an accumulated deficit of $1,066.0 million ⁵³. As of December 31, 2024, the accumulated deficit was $754.6 million ⁵⁴.

The company is a clinical stage company and has incurred significant operating losses since inception, with an accumulated deficit of $1,066.0 million ³⁰ as of December 31, 2025, and net losses of $311.4 million ³¹, $223.9 million ³², and $147.0 million ³³ for the years ended December 31, 2025, 2024, and 2023, respectively. The company will need to raise substantial additional funding, and as of December 31, 2025, it had cash and cash equivalents and marketable securities of $1,619.4 million ³⁴, which it expects will be sufficient to fund operations into 2029 ³⁵. The company's approach to the discovery and development of product candidates is novel and unproven, and no product candidate using a heterobifunctional degrader has been approved in the United States or Europe. The company is very early in its development efforts, and its STAT6 and IRF5 programs are in early clinical development with additional programs in preclinical development. The company depends heavily on the successful development of its lead programs, and if it is unable to advance them through the clinic for safety or efficacy reasons or commercialize its product candidates or experience significant delays, its business will be materially harmed. The company's current or future product candidates may cause adverse or other undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval.